Iluvien 190 µg implant (applic.) i.vitr. applic. Belgie - nizozemština - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

iluvien 190 µg implant (applic.) i.vitr. applic.

alimera sciences europe ltd. - fluocinolonacetonide 0,19 mg - intravitreaal implant in applicator - 190 µg - fluocinolonacetonide 0.19 mg - fluocinolone acetonide

Lipiodol Ultra Fluide 480 mg/ml inj. opl. i.arter./i.lymf. amp. Belgie - nizozemština - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lipiodol ultra fluide 480 mg/ml inj. opl. i.arter./i.lymf. amp.

guerbet - papaver, zaad, gejodeerde olie vetzuur ethylester - oplossing voor injectie - 480 mg i/ml - jodium 2320 mg - ethyl esters of iodised fatty acids

Micropaque 1 g/ml or./rect. opl. Belgie - nizozemština - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

micropaque 1 g/ml or./rect. opl.

guerbet - bariumsulfaat 100 g/100 ml - oplossing voor oraal/rectaal gebruik - 1 g/ml - bariumsulfaat 1000 mg/ml - barium sulfate without suspending agents

Tvenforz 5 mg/ml oogdruppels opl. druppelfl. Belgie - nizozemština - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tvenforz 5 mg/ml oogdruppels opl. druppelfl.

alcon sa-nv - tetracaïnehydrochloride 5 mg/ml - oogdruppels, oplossing - 5 mg/ml - tetracaïnehydrochloride 5 mg/ml - tetracaine

Byooviz Evropská unie - nizozemština - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Evropská unie - nizozemština - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Evropská unie - nizozemština - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).